MetaCap

DaVita Inc. (DVA)

NYSE: DVAHealth CareMisc Health and Biotechnology ServicesUSD

161.03+4.69 (+3.00%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

DVA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$10.13B
EPS (TTM)
$13.21
52-week range
101.00 – 247.49
Day range
157.20 – 162.99
Volume / Avg
730.12K / 738.70K
Beta
—

52-week range

$101.00$247.49

DVA stock today

Shares of DaVita (DVA) finished higher on Nov 20 at $161.03, a gain of 3.00% or $4.69 per share, versus the S&P 500's 3.70% decline. Shares are 34.9% below their 52-week high of $247.49, set on Aug 3, 2026 and 59.4% above the 52-week low of $101.00, in the middle of the past year's range. DVA is up 41.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 33.9%.

At 12.2x trailing earnings, DaVita trades below the peer-group median of 24.5x. Its forward P/E of 9.5x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About DaVita

Company profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers.

Industry
Misc Health and Biotechnology Services
CEO
Mr. Javier J. Rodriguez
Headquarters
Denver, CO
Employees
78,000
Website
davita.com

Financial highlights

Full financials

In fiscal 2025, DaVita generated $13.64 billion in revenue, up 6.5% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $746.8 million (-20.2% year over year), for a net margin of 5.5% versus a median of 6.7% in the prior 5 years. Operating margin was 15.0%.

DaVita annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$13.64B$12.82B$12.14B$11.61B$11.62B
Growth+6.46%+5.56%+4.57%-0.08%+0.59%
Net income$746.80M$936.34M$691.53M$560.40M$978.45M
EPS (diluted)$9.84$10.73$7.42$5.85$8.90

Analyst forecast

Forecast

Consensus (8 analysts)

buy

Avg. price target

$222.29+38.04%

  • Strong buy 0
  • Buy 3
  • Hold 3
  • Sell 0
  • Strong sell 2

Target range

Low $165.00High $287.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 29, 2026
EPS actual vs est.
$3.40 vs $3.78
Surprise
-10.05%

DVA news

All DVA news

DaVita peers

Health Care sector
DVA peer companies
CompanyPrice% ChgMarket capCompare
FMSFresenius Medical Care AG ADR20.44+1.54%$10.61Bvs DVA
SHCSotera Health Company15.91-1.85%$4.54Bvs DVA
PGNYProgyny Inc.35.71+0.73%$2.63Bvs DVA
AGLagilon health inc.90.24+0.83%$1.52Bvs DVA
VMDViemed Healthcare Inc.8.52-1.05%$322.85Mvs DVA
PARKPark Dental Partners Inc.17.03-6.79%$94.26Mvs DVA
CCELCryo-Cell International Inc.4.150.00%$33.46Mvs DVA
MGRXMangoceuticals Inc.0.1236-7.55%$2.75Mvs DVA

Indexes, lists and sector

DaVita stock FAQ

What is DaVita's stock price today?

DVA last traded at $161.03 as of Nov 20, 4:00 PM EST, up 3.00% on the day. Prices are delayed at least 15 minutes.

Does DaVita pay a dividend?

No. DaVita does not currently pay a regular cash dividend.

What is DVA's P/E ratio?

DVA trades at a trailing P/E ratio of 12.19 and a forward P/E of 9.52, compared with a median of 24.5 for its closest peers.

Is DaVita in the S&P 500?

Yes. DaVita (DVA) is a constituent of the S&P 500 index.

Who is DaVita's CEO?

Mr. Javier J. Rodriguez is the chief executive officer of DaVita Inc., which has about 78,000 employees.

Has DVA ever split its stock?

Yes. The most recent DVA stock split was a 2-for-1 split on Sep 9, 2013, one of 3 splits on record.

What is the DVA 52-week high?

The 52-week high for DVA is $247.49 and the 52-week low is $101.00. The stock is currently 34.9% below its high.

Compare DVA